Cargando…
Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial
Hepcidin is the key regulator of iron homeostasis but data are limited regarding its temporal response to iron therapy, and response to intravenous versus oral iron. In the 56-week, open-label, multicenter, prospective, randomized FIND-CKD study, 626 anemic patients with non-dialysis dependent chron...
Autores principales: | Gaillard, Carlo A., Bock, Andreas H., Carrera, Fernando, Eckardt, Kai-Uwe, Van Wyck, David B., Bansal, Sukhvinder S., Cronin, Maureen, Meier, Yvonne, Larroque, Sylvain, Roger, Simon D., Macdougall, Iain C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898697/ https://www.ncbi.nlm.nih.gov/pubmed/27276035 http://dx.doi.org/10.1371/journal.pone.0157063 |
Ejemplares similares
-
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
por: Roger, Simon D., et al.
Publicado: (2017) -
Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017) -
Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
por: Macdougall, Iain C., et al.
Publicado: (2017) -
The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2014) -
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)